Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 Q2- Text added to 2018 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
abiraterone, accredited, adrenergic, agonist, antagonist, antitubulin, bisindole, blocking, castration, cis, decision, docetaxel, entirety, enzalutamide, estrogen, exact, exempt, Exhibit, foregoing, fourth, human, inhibition, intravaginal, latency, muscarinic, Nonemployee, pipeline, promulgated, receptor, referenced, resignation, retirement, safer, sex, shrink, specialty, STI, super, text, toxicity, Trademark, transmission, triple, unable, unmet
Valuein 2018 Q2 filing- Value in 2018 Q3 filing
Original filings
Filing view